三联PSMA PET/CT-MRI-US融合活检在前列腺癌诊断中的前瞻性配对研究
该前瞻性单中心配对诊断准确性研究纳入308例活检初治男性,比较三联PSMA PET/CT-MRI-US融合活检与MRI-US融合活检及系统活检对临床显著前列腺癌(csPCa)的检出率。三联融合活检较MRI-US融合活检多检出4.9%的csPCa(95%CI 2.4%-7.3%;P<0.001),尤其在PSMA阳性病灶<10 mm和PI-RADS 4病灶中获益更明显,PSMA风险评分(AUC 0.933)可有效分层,模拟风险引导策略可减少约42%活检但漏诊2.3% csPCa。
要点
- 三联融合活检较MRI-US融合活检多检出4.9%的csPCa,需活检人数20.5。
- PSMA阳性病灶<10 mm和PI-RADS 4病灶获益最显著,分别提高8.3%和5.8%。
- PSMA风险评分AUC 0.933,模拟风险引导策略可减少约42%活检但漏诊2.3% csPCa。
核心结论
- 三联PSMA PET/CT-MRI-US融合活检在检测csPCa方面优于MRI-US融合活检,尤其对小PSMA阳性病灶和PI-RADS 4病灶。
- PSMA衍生风险评分可实现有效分层,模拟风险引导方法在测试集中显示减少活检的潜力。
- 研究结果需多中心验证后方可临床采用。
研究设计与样本
- 前瞻性、单中心、配对诊断准确性研究(STARD 2015;ChiCTR2400089436),纳入308例活检初治男性。
- 所有受试者在单次 session 中接受三联融合活检、MRI-US融合活检和系统活检。
- 主要终点为三联融合活检与MRI-US融合活检在患者层面csPCa(ISUP分级组≥2)检出率的绝对差异。
主要发现
- 三联融合活检较MRI-US融合活检多检出4.9%的csPCa(95%CI 2.4%-7.3%;P<0.001;需活检人数20.5)。
- PSMA阳性病灶<10 mm的获益为8.3%,PI-RADS 4病灶的获益为5.8%,多变量广义估计方程模型中获益持续存在。
- PSMA影像风险评分AUC为0.933,区分度高于PRIMARY和分子影像PSMA评分。
- 在测试集的回顾性模拟中,风险引导方法可避免约42%的活检,同时漏诊2.3%的csPCa。
关键数值与推荐
- csPCa定义为国际泌尿病理学会(ISUP)分级组≥2。
- 三联融合活检较MRI-US融合活检的csPCa检出绝对差异为4.9%(95%CI 2.4%-7.3%;P<0.001)。
- PSMA影像风险评分的AUC为0.933。
- 模拟风险引导方法可避免约42%的活检,漏诊2.3%的csPCa。
临床怎么用
- 在活检初治男性中,三联PSMA PET/CT-MRI-US融合活检可提高csPCa检出,尤其适用于小PSMA阳性病灶和PI-RADS 4病灶。
- PSMA衍生风险评分可用于风险分层,模拟风险引导策略可能减少活检数量,但需注意漏诊风险。
- 临床 adoption 前需多中心验证。
局限性
- 单中心设计。
- 测试集样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiparametric MRI (mpMRI)-ultrasound (US) fusion biopsy misses 8%-20% of clinically significant prostate cancer (csPCa), leaving a detection gap that prostate-specific membrane antigen (PSMA) PET/CT may help close. Whether incorporating PSMA into an MRI-US fusion platform improves csPCa detection has not been evaluated in a prospective paired design. We compared tri-modal PSMA PET/CT-MRI-US fusion biopsy with MRI-US fusion biopsy and systematic biopsy. METHODS: In this prospective, single-center, and paired diagnostic accuracy study (STARD 2015; ChiCTR2400089436), 308 biopsy-naive men underwent tri-modal fusion biopsy, MRI-US fusion biopsy, and systematic biopsy in a single session. The primary endpoint was the absolute difference in patient-level csPCa detection (International Society of Urological Pathology grade group ≥ 2) between tri-modal and MRI-US fusion biopsies. RESULTS: Tri-modal fusion detected 4.9% more csPCa than MRI-US fusion biopsy (95% confidence interval 2.4%-7.3%; P < 0.001; number needed to biopsy 20.5). The most significant gains were observed for PSMA-positive lesions < 10 mm (8.3%) and Prostate Imaging Reporting and Data System (PI-RADS) 4 lesions (5.8%), and this benefit persisted in multivariate generalized estimating equation models. The PSMA imaging-based risk score (area under the curve, 0.933) showed higher discrimination than the PRIMARY and molecular imaging PSMA scores. In a retrospective simulation using the test set, a risk-guided approach would have avoided approximately 42% of biopsies while missing 2.3% of csPCa. Limitations include the single-center design and the small test set. CONCLUSION: Tri-modal fusion was superior to MRI-US fusion biopsy in detecting csPCa, particularly in small PSMA-positive and PI-RADS 4 lesions. A PSMA-derived risk score enabled effective stratification, and in the test set, a simulated risk-guided approach showed potential for biopsy reduction. These findings require multicenter validation before clinical adoption. TRIAL REGISTRATION: ChiCTR2400089436 (Chinese Clinical Trial Registry, http://www.chictr.org.cn/ , registered 2024-09-09).
引用
- Huang C, Jin L, Sun Y, et al. Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42742683. doi:10.1007/s00259-026-08181-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。